 |
|
| Blog results | Results 1 - 10 of about 6,624 for capecitabine breast cancer. (0.34 seconds) |
| Sorted by relevance Sort by date |
| 12 Nov 2009 by HSPDi The analysis, conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology, shows that the addition of capecitabine (Xeloda) to treat women at intermediate to high risk of early breast cancer recurrence reduced the ... pharma news - http://www.pharmajobs.co.uk/blog/ |
| 11 Nov 2009 Finland, November 11/PRNewswire/ -- An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as ... Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html [ More results from Drugs.com - Clinical Trials ] |
| 17 Nov 2009 by Syn-chemist Recently, Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in ... Med-Chemist - http://synchemist.blogspot.com/ |
| 10 Nov 2009 The study involved 1500 women with axillary node-positive or high-risk node-negative breast cancer randomised to either 3 cycles of capecitabine and docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine ... NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/ [ More results from NeLM - News ] |
| 11 Nov 2009 Finland November 11 /- ... - This is a third party press release. It will be issued by the Fi... - FinXX a Large Phase III Randomised Study in Women With Early B... An analysis conducted by the Finnish Breast Cancer Group and publi... ... Latest Medical Technology from Bio-Medicine.Org - http://www.bio-medicine.org/medicine-technology... [ More results from Latest Medical Technology from Bio-Medicine.Org ] |
| 11 Nov 2009 Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence- This is a third party press release. It will be issued by the Finnish Breast Cancer Group on Wednesday 11 ... Pharmaceutical Events (November-2009) - http://www.pharmiweb.com/ [ More results from Pharmaceutical Events (November-2009) ] |
| 12 Nov 2009 by Dr. NICK Finnish researchers report that for patients with moderate- to high-risk early breast cancer, capecitabine combined with a regimen containing a taxane and an anthracycline was more effective in lowering the risk for disease recurrence ... CANCER AND IMPORTANT MEDICAL NEWS - http://cancerology.blogspot.com/ [ More results from CANCER AND IMPORTANT MEDICAL NEWS ] |
| 12 Nov 2009 by DrugsNews An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had ... Drugs Reviews | Dugs News - http://www.drugs-review.com/ [ More results from Drugs Reviews | Dugs News ] |
| 15 Nov 2009 Although capecitabine added to chemotherapy for breast cancer improves survival rates, side-effects will force some patients to discontinue the treatment, according to trials. A report by Professor Heikki Joensuu and colleagues at ... Pharmacy Europe - http://www.pharmacyeurope.net/rss.asp - References [ More results from Pharmacy Europe ] |
| 11 Nov 2009 Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: An open-label, randomised controlled trial. Breast News - http://www.mdlinx.com/HemeOncLinx/news.cfm/newspage/1/spec_id/17/subspec_id/387 |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
